Bionano Genomics (NASDAQ:BNGO) and Thermo Fisher Scientific (NYSE:TMO) Head to Head Analysis

Thermo Fisher Scientific (NYSE:TMO) and Bionano Genomics (NASDAQ:BNGO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Insider & Institutional Ownership

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 11.3% of Bionano Genomics shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Bionano Genomics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56 billion	5.78	$6.70 billion	$18.96	36.75
Bionano Genomics	$28.51 million	0.56	-$26.40 million	($3.02)	-0.38

Thermo Fisher Scientific has higher revenue and earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Thermo Fisher Scientific and Bionano Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	14.94%	17.33%	8.18%
Bionano Genomics	-106.58%	-78.78%	-48.54%

Analyst Ratings

This is a breakdown of recent recommendations for Thermo Fisher Scientific and Bionano Genomics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	1	4	18	2	2.84
Bionano Genomics	1	0	1	0	2.00

Thermo Fisher Scientific presently has a consensus price target of $689.10, indicating a potential downside of 1.10%. Bionano Genomics has a consensus price target of $6.00, indicating a potential upside of 421.74%. Given Bionano Genomics’ higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Thermo Fisher Scientific.

Summary

Thermo Fisher Scientific beats Bionano Genomics on 12 of the 15 factors compared between the two stocks.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

About Bionano Genomics

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.